BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38154806)

  • 1. Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Blas L; Shiota M; Tanegashima T; Tsukahara S; Ueda S; Mutaguchi J; Goto S; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
    Int J Urol; 2024 Apr; 31(4):404-408. PubMed ID: 38154806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the "optimal PSA follow-up schedule after radical prostatectomy" in a new cohort.
    Yanai Y; Matsumoto K; Kosaka T; Takeda T; Tanaka N; Morita S; Mizuno R; Shinojima T; Asanuma H; Oya M
    Int J Clin Oncol; 2020 Jul; 25(7):1393-1397. PubMed ID: 32285217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
    Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
    Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
    Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk grouping algorithm for predicting factors of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Micoogullari U; Cakici MC; Kisa E; Canda AE; Kilic FU; Ardicoglu A; Altinova S; Atmaca AF; Akbulut Z; Balbay MD
    Int J Clin Pract; 2021 Oct; 75(10):e14495. PubMed ID: 34155724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K; Niwa N; Hattori S; Takeda T; Morita S; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Asanuma H; Oya M
    Urol Oncol; 2018 Jul; 36(7):341.e9-341.e14. PubMed ID: 29730065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
    J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
    Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
    BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
    Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
    Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression.
    Chow K; Herrera P; Stuchbery R; Peters JS; Costello AJ; Hovens CM; Corcoran NM
    BJU Int; 2019 Jun; 123(6):976-984. PubMed ID: 30248237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
    Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
    BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
    Chung JH; Jeong JY; Lee JY; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    PLoS One; 2021; 16(5):e0249709. PubMed ID: 33939714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.